EXTENDED SURVIVAL AND FUNCTION OF PERIPHERAL-NERVE ALLOGRAFTS AFTER CESSATION OF LONG-TERM CYCLOSPORINE ADMINISTRATION IN RATS

被引:14
|
作者
FRAZIER, J
YU, L
RHEE, E
SHAW, L
LAROSSA, D
ROSTAMI, A
机构
[1] Bronx-Lebanon Hospital Center, Bronx, N.Y., Hospital of the University of Pennsylvania, Philadelphia, Pa
来源
JOURNAL OF HAND SURGERY-AMERICAN VOLUME | 1993年 / 18A卷 / 01期
关键词
D O I
10.1016/0363-5023(93)90252-X
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
To determine whether survival and function of peripheral nerve allografts are possible after cessation of long-term cyclosporin (CsA) treatment, we grafted 4.25 cm Lewis rat peripheral nerve allografts (n = 22) into tibial nerve gaps in recipient brown Norway rats. Allograft groups received CsA (15 mg/kg) subcutaneously every day for 20 days and then biweekly for either 5 or 8 months after transplantation. The control group, brown Norway rats with isografts from brown Norway donor rats (n = 2), also received identical CsA treatment. Semimonthly electrophysiologic studies were done from postoperative week 13 until the animals were killed (up to 79 weeks). The corresponding CsA levels in the nerve and blood were recorded from cessation of CsA up to 58 weeks after surgery. No electrophysiologic signs of rejection were observed in any of the 22 allograft recipients treated with CsA for up to 8 months or in 17 of the 22 observed for up to 58 weeks after cessation of CsA. Overall, 5 of 22 allografts were rejected in the first 8 weeks after discontinuation of CsA. Signs of rejection occurred only in the 5-month treatment group and followed the large initial drop in CsA blood level (from 1010 ng/ml to <25 ng/ml) that occurred within the first 6 weeks after CsA cessation. The two isograft controls demonstrated no electrophysiologic signs of rejection up to 58 weeks after surgery. Peripheral nerve allografts in the rat can regenerate and function on long-term CsA; after cessation of CsA, they can function for extended periods of time without signs of rejection if trace amounts of CsA are present. The clinical implication is that allograft recipients may require only short courses of CsA; this would limit the need for and complications of long-term CsA therapy.
引用
收藏
页码:100 / 106
页数:7
相关论文
共 50 条